Pacritinib More Effective at Spleen Volume Reduction Than Best Available Therapy in Myelofibrosis

Treatment with the multityrosine kinase inhibitor pacritinib resulted in a significant reduction in spleen volume compared with best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia, according to a study presented at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition. For the phase 3 PERSIST-2 study ( identifier: NCT02055781), investigators…

Next post in Web Exclusives